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Abstract
Objective: To summarize current views on the pathophysiology, risk factors, prevention, clinical features,
and management of Ovarian Hyperstimulation Syndrome (OHSS).
Design: Literature review
Results: OHSS is a condition characterized by increased capillary permeability, and experimental evidence
has identified a provocative link to pathologic vasoactive cytokine actions. Although the ultimate physiologic
mechanism of OHSS is not yet known, there are well-known risk factors that must be considered during the
administration of medications to treat infertility. Clinical features are consequences of third-spaced intravas-
cular fluid, and OHSS may become life-threatening secondary to thromboembolism or compromised pulmo-
nary or cardiovascular function. Cornerstones of prevention have historically included cycle cancellation,
coasting, decreased dosing of human chorionic gonadotropin (hCG) trigger, use of an agonist trigger, and
cryopreservation of all embryos. Newer methods of prevention include the administration of a dopamine
agonist medication. Management options for OHSS include outpatient transvaginal paracentesis, outpatient
transabdominal paracentesis, and inpatient hospitalization with or without paracentesis.
Conclusions: OHSS continues to be a serious complication of assisted reproductive therapy (ART), with
no universally agreed upon best method of prevention. Coasting and cryopreservation of all embryos are the
most commonly used approaches in the literature, but cycle cancellation is the only method that can completely
prevent the development of OHSS. Dopamine agonists are currently being investigated to both prevent and
improve the clinical course in OHSS. Recent publications suggest that outpatient paracentesis both prevents
the need for inpatient hospitalization and is a cost-effective strategy.
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Introduction
Ovarian Hyperstimulation Syndrome (OHSS) is a rare,
iatrogenic complication of ovarian stimulation with folli-
cle stimulating hormone (FSH) medications. OHSS was
first described in 1943, and the first fatal cases were docu-
mented in 1951. Severe OHSS is estimated to occur in
approximately 1% of all gonadotropin cycles. A study
done in 2005 using data from the Finnish registry reported
an incidence of severe OHSS of 1.4% per cycle, with an
individual risk per patient of 2.3% over a mean number of
3.3 cycles (1). Using population data from European
(2003) and United States (2005) in vitro fertilization (IVF)
databases, it can be estimated that there were a total of
300,000 IVF cycles reported in Europe and 130,000 IVF
cycles reported in the United States, for a total of approx-
imately 430,000 total IVF cycles annually. If the incidence
of severe OHSS were 1.4% per cycle in these 430,000 total
IVF cycles, this calculation yields approximately 6,020
patients per year predicted to develop severe OHSS. This
calculation lends important perspective on the potential
impact of this condition. Notably, mortality is rare but
several cases have been reported.
Materials and Methods
Literature review was performed by a single author
(MMA) utilizing the following search terms in the
PubMed database: ovarian hyperstimulation syndrome, in
vitro fertilization, IVF, trigger, GnRH agonist, embryo
cryopreservation, albumin, dopamine agonist, and para-
centesis.
Results
Pathophysiology
The underlying feature of OHSS is increased capillary
permeability leading to a fluid shift from the intravascular
space to third space compartments. Factors including mol-
ecules in the renin-angiotensin system and vascular endo-
thelial growth factor (VEGF) have been implicated in the
pathophysiology of OHSS. The renin-angiotensin system
is widely known to regulate fluid balance, and was among
the first systems investigated as a potential contributor to
the findings in OHSS. The presence of an ovarian renin-
angiotensin system has been long identified, and Derck et
al. in 1987 found follicular fluid (FF) from IVF patients
stimulated with human menopausal/human chorionic
gonadotropin to have markedly elevated prorenin levels
(40x plasma) and renin levels (10x plasma) compared to
unstimulated controls (2). Likewise, Lightman et al. iden-
tified elevated FF levels of renin, angiotensin II, and
angiotensin III from stimulated compared to unstimulated
controls (3).
More recently, investigations have shifted to focus on the
relationship of VEGF and OHSS. Vascular endothelial
growth factor is a vasoactive glycoprotein (cytokine)
which stimulates endothelial cell proliferation, cell per-
meability, and angiogenesis. VEGF mRNA has been
found to be expressed in granulosa cell culture. Further-
more, VEGF levels have been shown to increase in
response to the administration of luteinizing hormone
(LH), follicle stimulating hormone (FSH), and hCG in
granulosa cell culture. Levin et al. evaluated the relation-
ship between VEGF and OHSS in an elegant series of
experiments (4). They studied FF from 80 women under-
going gonadotropin induction for the treatment of infer-
tility. The FF samples were separated into four groups (I
– IV) based on the number of oocytes retrieved. Using an
in vitro endothelial cell permeability assay, the authors
found that patients producing more eggs had increased
capillary permeability. Furthermore, there was a direct
correlation between the number of eggs retrieved and the
FF VEGF level, with statistically significantly more
VEGF in FF from patients who produced more oocytes.
They investigated the mechanisms of increased cell per-
meability using an actin stain of tight junctions in endo-
thelial cells. Treatment with FF and VEGF produced equal
redistribution of the actin filaments in the tight junctions,
suggesting that VEGF is the FF component responsible
for the changes in vascular permeability characteristic of
OHSS.
Other possible mechanisms for the development of OHSS
have been suggested, including FSH receptor variability.
De Leener et al. have investigated FSH receptor mutations
and the development of spontaneous OHSS in order to
shed further light on spontaneous and iatrogenic induction
of OHSS (5).
Risk Factors
There are many well-known and clearly-documented risk
factors for the development of OHSS including: young
age, low body mass index (BMI), polycystic ovarian syn-
drome (PCOS), allergic history, high antral follicle count,
high doses of gonadotropins, high or rapidly rising estra-
diol levels, large numbers of large and medium-sized fol-
licles, large numbers of eggs retrieved, high or repeated
doses of hCG, pregnancy, and prior OHSS (6). Of these
risk factors, high or rapidly rising estradiol levels are par-
ticularly unreliable and over-rated predictors of OHSS
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n(7). An estradiol cut-off of 3,000 pg/mL will miss 2/3 of
patients with severe OHSS. Counting the number of
12mm follicles is actually a better predictor of OHSS than
serum estradiol levels, and the combination of an estradiol
level of 5,000 pg/mL and eighteen 12mm follicles was
found to be the best predictor of OHSS in this study,
yielding a sensitivity of 83% and specificity of 84% (7).
The relative uselessness of serum estradiol level to predict
the development of OHSS was confirmed in a study done
at our center, in which 183 patients with OHSS requiring
hospital admission or outpatient transvaginal paracentesis
were evaluated. Of these 183 patients who required an
intervention secondary to OHSS, 71% had a peak estradiol
level less than 3,000 pg/mL, 12% had a peak estradiol
between 3,000 pg/mL and 4,000 pg/mL, and only 17% had
a peak estradiol greater than 4,000 pg/mL (Boston IVF
data, 1999–2007, unpublished).
Prevention
Cornerstones of OHSS prevention have historically inclu-
ded the following strategies: cycle cancellation with with-
holding of hCG trigger, coasting, decreasing the dose of
hCG trigger, agonist trigger, and cryopreservation of all
embryos. Newer techniques include intravenous (IV)
albumin at the time of egg retrieval and the use of dopa-
mine agonists.
IVF cycle cancellation is the most effective preventative
technique, but is emotionally and financially stressful for
all involved. Cycle cancellation is generally reserved for
patients with a history of severe OHSS in a prior cycle and
in cases of total loss of control of the cycle.
Coasting involves temporarily stopping gonadotropin
administration and postponing the hCG trigger until the
estradiol level is lower. The proposed mechanism of coast-
ing is as follows: lower gonadotropin stimulation leads to
decreased LH receptors, leading to decreased luteiniza-
tion, and subsequent decreased VEGF levels. Lower gona-
dotropin stimulation may also increase the rate of granu-
losa cell apoptosis, especially of smaller follicles. Coast-
ing lowers the level of follicular fluid VEGF, thereby
potentially preventing the development of OHSS (8).
Close evaluation of the literature on coasting and OHSS
reveals that the true effectiveness of coasting cannot be
determined since there are no randomized, controlled tri-
als investigating the implementation and outcomes of this
strategy. The documented indications for coasting are var-
iable among current studies, as is the target estradiol level
(typically approximately 3,000 pg/mL). Coasting does not
even totally prevent the development of OHSS, and in a
study by Delvigne et al., 16% of patients who were coasted
still had ascites and 2.5% still required hospitalization (9).
Furthermore, coasting for greater than four days has been
shown to result in lower pregnancy and implantation rates
(10,11).
The strategy of using a lower dose of hCG trigger is inclu-
ded among options to prevent the development of OHSS.
Schmidt et al. in 2004 did a retrospective of high respond-
ers, and included 194 IVF cycles (12). In these patients, if
the estradiol level ranged from 2,500 pg/mL to 4,000 pg/
mL, the patients were given 5,000 IU hCG trigger. If the
estradiol level was above 4,000 pg/mL, they were given a
lower trigger dose of only 3,300 IU hCG. Despite the
decreased dose of hCG trigger administered, there was no
difference in OHSS, but there was excellent oocyte matu-
ration even with a dose of hCG of 3,300 IU. A study by
Kolibianakis et al. in patients with PCOS showed similar
results when patients were administered either an hCG
trigger of 10,000 IU, 5,000 IU, or 2,500 IU (13). In these
groups, there was no difference in pregnancy rate (29%
vs. 30.8% vs. 34.8%) or the development of severe OHSS
(3.8% vs. 3.8% vs. 0%) even with an hCG trigger as low
as 2,500 IU. Unfortunately, although theoretically it
makes sense to reduce the dose of hCG, there is little data
to support this practice and studies are either limited by
small sample size or not powered to detect a difference.
Using an agonist medication to trigger ovulation has been
proposed as another strategy to prevent OHSS. Agonist
trigger can only be used in the setting of an antagonist
protocol, and Leuprolide 1mg or Triptorelin 0.2mg have
been suggested. This method was first described by Itsko-
vitz-Eldor in 2000 in the treatment of eight patients with
OHSS (14). Review of the literature identifies 23 articles
published on the topic of agonist trigger and prevention of
OHSS. A meta-analysis by Griesinger et al. in 2006 iden-
tified only 3/23 of these studies which met criteria for
meta-analysis (randomized, controlled trials) (15). Com-
paring pregnancy rate per patient randomized to GnRH
agonist vs. hCG trigger identified no difference in number
of oocytes retrieved, fertilization rate, or embryo score.
No patients randomized to either GnRH agonist or hCG
trigger developed OHSS; but there was the suggestion of
a lower pregnancy rate in patients who had GnRH agonist
trigger, possibly due to a luteal support problem (15).
Cryopreservation of all embryos in patients with OHSS or
at risk for developing OHSS is a fifth strategy which has
been employed. Sills et al. in 2008 analyzed outcomes in
patients undergoing elective embryo cryopreservation to
prophylax against the development of OHSS (16). They
identified 51/2,892 IVF cycles (1.8%) with patients who
were at risk for OHSS (> 20 oocytes retrieved and pres-
ence of documented ascites) and had elective cryopreser-
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oocytes retrieved was 23 and mean number of 2PN
embryos frozen was 14. The mean number of days from
embryo cryopreservation to date of thaw embryo transfer
was 115 (range 30–377), and embryo blastulation rate was
88%. Finally, the live birth rate per embryo transfer was
an excellent 43.6% in these patients.
Certainly the concept of cryopreservation of all embryos
seems logical as a strategy to prevent OHSS given that
OHSS is more common and more severe with pregnancy
due to hCG-induced intrinsic ovarian stimulation. How-
ever, the Cochrane review found insufficient evidence in
the literature to support the routine practice of embryo
cryopreservation to prevent OHSS (17). As with all meth-
ods, it may reduce but not eliminate OHSS. Other studies
evaluating the usefulness of embryo cryopreservation to
prevent OHSS have shown either equivalence between
cryopreservation and coasting (18) or equivalence
between cryopreservation and administration of IV albu-
min (19), but no overwhelming superiority of embryo cry-
opreservation.
The administration of IV albumin has been suggested as
an alternate method to prophylax against the development
of OHSS. Literature review identifies the largest and best
study investigating this topic to be a randomized, control-
led trial by Bellver et al. in 2003 (20). In this study of 976
patients at high risk for the development of OHSS (20
eggs), the patients were randomized to either the admin-
istration of IV albumin 40 gm at the time of vaginal oocyte
retrieval or a placebo arm receiving no treatment x 30
minutes. They found no difference in the number of
patients requiring paracentesis to treat OHSS, need for
hospitalization, or time to resolution of symptoms. They
concluded that there was no benefit to giving IV albumin
prophylactically, and that the theoretical risks of trans-
mission of prions, viruses, or Creutzfeld-Jacob disease
outweighed any theoretical potential benefit.
Finally, the most recently suggested strategy to prevent
the development of OHSS is the use of dopamine agonists
such as Cabergoline. The proposed mechanism is inhibi-
tion of phosphorylation of the VEGF receptor by Caber-
goline, thereby preventing increased capillary permeabil-
ity, the main action of VEGF (21). The dopamine agonist
Cabergoline has been investigated in healthy egg donors
at risk for OHSS (20 or more oocytes) by Alvarez et al. in
2007 (22). In this study, patients were assigned to receive
either Cabergoline 0.5mg/day for 8 days starting on the
day of hCG (35 patients) or placebo (32 patients). All
patients underwent evaluation for OHSS, including serum
hematocrit, ultrasound to evaluate for ascites, and mag-
netic resonance imaging (MRI) for ovarian venous per-
meability. They found that in the women who received
Cabergoline, the ascites volume was statistically signifi-
cantly lower than in those who received placebo. They
also found that the percentage of women who developed
moderate OHSS was statistically significantly lower in
those patients who received Cabergoline (7/35 [20%] vs.
14/32 [43.8%]). There was no difference in the percentage
of patients in each group who developed severe OHSS.
Classification and Clinical Features
There have been many different classification systems for
OHSS proposed, which generally identify a mild, moder-
ate, and severe subtype with varying internal grades of
severity. In order to simplify the classification of OHSS,
we use a classification system adapted from that proposed
by the Royal College of Obstetricians & Gynaecologists
in 2006 (23). We identify mild OHSS, in which patients
have abdominal bloating and mild abdominal pain; mod-
erate OHSS, characterized by nausea, vomiting, moderate
abdominal pain, and ultrasound evidence of ascites; severe
OHSS, identifiable by clinical ascites, oliguria, hematocrit
> 45%, and hypoproteinemia; and critical OHSS, with
tense ascites, oliguria or anuria, hematocrit > 55%, and
white blood count > 25,000.
The clinical features of OHSS are easily identifiable by
the above classification strategy and are logical in the
context of the underlying pathophysiology of increased
capillary permeability. Patients with moderate OHSS
complain of lower abdominal pain, abdominal distention,
and gastrointestinal symptoms including nausea, vomit-
ing, and diarrhea. Patients classified as having severe
OHSS have rapid weight gain, tense ascites, hemody-
namic instability, respiratory difficulty, progressive oli-
guria, and laboratory abnormalities including hematocrit
> 48%, hyponatremia (< 135mEq/L), hyperkalemia
(>5.0mEq/L), and elevated creatinine (>1.2mg/dL).
The clinical features found in each organ system can also
be identified, and patients with OHSS of increasing
severity experience increased numbers of affected organ
systems (24). Gastrointestinal system findings include
ascites (third-spacing of fluid), paralytic ileus, and
enlarged ovaries. Pulmonary system findings include
pleural effusions, restrictive lung disease from ascites or
paralytic ileus, and ARDS. Cardiovascular system find-
ings include decreased intravascular volume, decreased
blood pressure, decreased central venous perfusion, and
compensatory increased heart rate and cardiac output with
arterial vasodilation. Coagulation abnormalities include
hemoconcentration, increased estrogen level leading to
hypercoagulability, and thrombosis (venous > arterial).
Renal system findings include decreased renal perfusion
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findings may include hepatic edema. Constitutional symp-
toms occur as well, with 50% of severe cases presenting
with elevated temperature of non-infectious etiology. The
etiology of hyperthermia is presently unclear, and may be
due to cytokines or prostaglandins. Hematologic findings
include increased hematocrit (secondary to increased
capillary permeability and fluid loss) and elevated white
blood cell count, a multifactorial finding associated with
elevated estrogen level, prostaglandins, and dilution.
Gynecologic findings include enlarged ovaries which may
torse or rupture. Finally, electrolyte findings classically
include hyponatremia (secondary to increased antidiuretic
hormone due to decreased intravascular volume) and
hyperkalemia (secondary to the renal sodium/potassium
pump alterations).
Outpatient Management
Paracentesis of abdominal ascites was first described in
1994, with the use of outpatient abdominal paracentesis
recommended to prevent hospitalization (25). In 1998,
aggressive outpatient single transvaginal paracentesis
(and IV albumin) was identified to prevent hospitalization
(26). Subsequently, in 2000 repeated transvaginal para-
centesis (one to three times) and IV albumin was found to
prevent hospitalization (27). In 2008, we performed a ret-
rospective review at our center of all patients diagnosed
with OHSS requiring paracentesis, hospitalization, or
expectant management (28). Between 1999 and 2007,
from a total of 9,707 patients (20,538 IVF cycles), 183
patients were identified with the diagnosis of OHSS (1.8%
of patients). In 2002, we began using outpatient transva-
ginal paracentesis in the management of OHSS. The tech-
nique for outpatient transvaginal paracentesis that we
employ involves the standard vaginal oocyte retrieval set-
up. The tubing is removed from the vaginal oocyte
retrieval needle, and the needle hub is attached to standard
wall suction tubing set at wall suction pressure of 200mm
mercury. The tubing is attached to wall suction, the needle
advanced through the vaginal wall into the peritoneal cav-
ity, and as much fluid is removed as can be removed.
In our review of the experience with outpatient transva-
ginal paracentesis in the management of OHSS, we iden-
tified 146 paracenteses performed in 96 patients. The
majority of patients underwent a single paracentesis
(50/96 patients, 52%), 36% (35/96 patients) required a
second, 8% (8/96 patients) underwent a third, 3% (3/96
patients) underwent a fourth, and one patient (1%)
required five paracenteses. The mean volume of ascites
fluid removed was 2,155mL (range 500 – 4,500cc). We
found that with the initiation of outpatient transvaginal
paracentesis as the primary management for OHSS in
2002, there was a dramatic decrease in the number of
patients requiring hospitalization for OHSS. We identified
no complications from paracentesis, and all patients had
symptomatic improvement.
A recent cost analysis was published comparing the cost
of outpatient management of OHSS with paracentesis ver-
sus inpatient management (29). Using mathematical mod-
eling, the authors estimated that conservative inpatient
management of OHSS would cost $10,099 compared to
$1,954 for outpatient management using paracentesis.
Given this dramatic difference in costs, they concluded
that early outpatient paracentesis is the most cost-effective
management strategy for moderate to severe OHSS.
Clearly, outpatient management of patients with OHSS
must be diligently enacted on the part of both the provider
and the patient. We instruct patients who are being man-
aged as outpatients on the symptoms of OHSS, with strict
instructions to contact their team immediately with any
worsening symptoms. They are instructed to avoid excess
fluid intake and drink “to thirst”, approximately 1 liter
daily. “Sports drinks” can be used if desired. They are
given prescriptions for analgesia and antiemetics as nee-
ded. Strenuous activity and intercourse are to be avoided,
but we advise against strict bedrest. Patients are asked to
record daily weight and estimated daily urine output (or
number of voids and degree of concentration). Progester-
one supplementation is continued in the luteal phase, but
supplementation is never done with hCG. In patients diag-
nosed with moderate or severe OHSS, we check baseline
and serial serum laboratory values including: baseline
clotting studies, hematocrit, white blood cell count, elec-
trolytes, BUN, creatinine, liver function tests, and protein.
We check ultrasound examinations for ascites, ovarian
dimensions, and pleural effusions. Chest roentogram is
ordered if patients complain of pulmonary difficulties.
Echocardiogram and electrocardiograms are ordered if
there is suspicion of pericardial effusion. All patients with
OHSS being managed as outpatients are examined by a
physician, with routine examination always including
vital signs (blood pressure, pulse, weight), pulmonary
exam, cardiovascular exam, abdominal exam, and waist
circumference measurement. A flowsheet with the key
symptoms and measurements is given to all patients, along
with instructions for form completion.
Inpatient Management
In a small percentage of patients, hospitalization for OHSS
will be required. Indications for hospitalization include
social factors such as patients who live far away from
medical care. Medical indications for hospitalization
include sicker patients who have symptoms that cannot be
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nmanaged on an outpatient basis. Such situations include
severe abdominal pain or peritonitis, severe nausea or
emesis, inability to tolerate oral intake, oliguria, pulmo-
nary compromise, hypotension, dizziness, severe electro-
lyte imbalance, and severe hemoconcentration. In our cen-
ter, the decision for inpatient hospitalization is made at the
doctor’s discretion following clinical evaluation. In our
review of the experience with outpatient management of
OHSS, we identified that since the introduction of aggres-
sive outpatient transvaginal paracentesis in 2002, the
majority of patients with moderate and severe OHSS have
been managed as outpatients.
If hospitalization is required for OHSS, however, we
closely manage fluid balance, closely follow laboratory
results, and do system-focused therapies as needed.
Regarding fluid management, it is critical to correct hemo-
concentration; thus, we recommend an initial IV fluid
bolus of 500–1,000cc normal saline (NS) over the first
hour of admission, followed by rehydration at a decreased
rate of 30cc/hour using D5NS titrated to urine output. We
reduce oral fluid intake to thirst and patient comfort. Albu-
min (25%) may be needed for intravascular volume reple-
tion, in which case 50 –100gm of IV albumin is infused
over 4 hours and repeated at 4–12 hour intervals as needed.
Hyperkalemia is treated in the standard manner with
Kayexelate, insulin/glucose, sodium bicarbonate, or albu-
terol as needed. Rarely, diuretics such as Lasix are given,
but extreme caution is used in the administration of diu-
retics to patients with OHSS given their known intravas-
cular volume depletion. Other inpatient management
strategies include paracentesis if needed. Thromboembo-
lism prevention is critical given the hypercoagulatory state
of OHSS, and we generally recommend both venous sup-
port stockings and anticoagulants such as heparin 5,000 U
subcutaneously twice daily. Occasionally, patients may
need intensive care unit admission for thromboembolic
complications, renal failure, or if invasive hemodynamic
monitoring is indicated (central venous pressure, pulmo-
nary capillary wedge pressure).
Discussion
Review of the literature identifies recent research into the
pathophysiology of OHSS which has shed light on VEGF
and other angiogenic factors as key targets, but definitive
findings on the outcomes and benefits of different strat-
egies for the prevention of OHSS continue to be lacking.
Given the shortage of clear data on which to base deci-
sions, clinician opinions are divided regarding the best
possible method for the prevention of OHSS, as shown in
a paper by Delvigne and Rozenberg in 2001 (30). In this
study, clinicians were presented with a case of a 25 year
old patient with PCOS undergoing IVF with ICSI, a BMI
of 23, and multiple allergies undergoing agonist stimula-
tion protocol using 150U HMG/day x 12 days. The case
patient had a peak estradiol level of 6,590 pg/mL and had
developed 20 follicles on transvaginal ultrasound. When
asked the question “what would you do?” 14% of physi-
cians stated that they would cancel the cycle, 8% would
proceed with the vaginal oocyte retrieval as usual, and
78% wanted to do one of the preventative measures
against OHSS. Of the physicians desiring to pursue a pre-
ventative measure, the majority (60%) would have rec-
ommended coasting to decrease the estradiol level, 36%
would have advised the use of IV albumen, and 33%
would have cryopreserved all embryos, even though the
data supporting these preventative strategies is borderline
at best.
We have found the technique of aggressive outpatient
transvaginal paracentesis to manage OHSS in patients
with moderate or severe disease to rapidly improve both
patient symptoms and laboratory abnormalities. Further,
using this strategy has decreased the need for inpatient
hospitalization at our center. Given the favorable cost
analysis proposed by Csokmay et al., a management algo-
rithm for OHSS that includes frequent outpatient transva-
ginal paracentesis seems both medically sound and eco-
nomically advantageous (29).
In summary, OHSS continues to be a serious complication
of ART and conclusions are lacking in the literature
regarding the best method of prevention. Coasting is the
most common method used, followed by cryopreservation
of all embryos. Data from randomized, controlled trials is
limited for all suggested preventative strategies. Further-
more, it is difficult to prove that one method is superior to
another due to the overall low incidence of severe OHSS.
Given these limitations, we use the following approach in
the prevention of OHSS: (1) coasting when estradiol lev-
els are very high or there are too many medium range fol-
licles; (2) we always give the standard dose of hCG and
never cancel the cycle regardless of peak estradiol level;
(3) we do not use IV albumin or dopamine agonists; (4)
cryopreserve all embryos if the patient is symptomatic on
the day of scheduled embryo transfer; and (5) aggressively
use transvaginal paracentesis for moderate to severe
OHSS.
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